Lakefront Biotherapeutics (LKFT) launched a new share repurchase program of up to €50M after completing its initial €50M buyback on October 16, 2026 (which totaled ~1.99M ordinary shares).
Effective November 16, 2026, through no later than March 31, 2027, the new mandate authorizes repurchase
